Plasma IL-18 and IL-18BP are altered differently in reverse remodeling following aortic valve replacement

Scandinavian Cardiovascular Journal

Volumn 44, Issue 2, 2010, Pages 113-118

  Majak, Peter ^a   Bjørnstad, Johannes ^a,b   Vengen, Øystein A ^a   Neverdal, Nils O ^a   Husebye, Trygve ^b   Woldbæk, Per ^a   Pepper, John ^c   Lie, Mons ^a   Christensen, Geir ^a,b   Tønnessen, Theis ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Aortic stenosis; Aortic valve replacement; Interleukin 18; Remodeling

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN;

AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION TEST; HEART VENTRICLE REMODELING; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; BIOPROSTHESIS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER, COLOR; EXERCISE TEST; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEART VENTRICLES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77949616209     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017430903426902     Document Type: Article

References (19)

1. Perez de AD, Lees B, Flather M, Nugara F, Husebye T, Jasinski M, et al. Randomized comparison of stentless versus stented valves for aortic stenosis: Effects on left ventricular mass. Circulation. 2005;112:2696-2702
2. Lund O, Kristensen LH, Baandrup U, Hansen OK, Nielsen TT, Emmertsen K, et al. Myocardial structure as a determinant of pre- and postoperative ventricular function and longterm prognosis after valve replacement for aortic stenosis. Eur Heart J. 1998;19:1099-1108
3. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation. 1989;79:744-755
4. Tønnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 1995;76:767-772
5. Woldbaek PR, Tønnessen T, Henriksen UL, Florholmen G, Lunde PK, Lyberg T, et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res. 2003;59:122-131
6. Neverdal NO, Knudsen CW, Husebye T, Vengen OA, Pepper J, Lie M, et al. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis-one year follow-up. Eur J Heart Fail. 2006;8: 257-262
7. Woldbaek PR, Sande JB, Strømme TA, Lunde PK, Djurovic S, Lyberg T, et al. Daily administration of interleukin- 18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol. 2005;289:H708-H714.
8. Chandrasekar B, Mummidi S, Claycomb WC, Mestril R, Nemer M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositidedependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem. 2005;280:4553-4567
9. Colston JT, Boylston WH, Feldman MD, Jenkinson CP, de la Rosa SD, Barton A, et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun. 2007; 354:552-558
10. Platis A, Yu Q, Moore D, Khojeini E, Tsau P, Larson D. The effect of daily administration of IL-18 on cardiac structure and function. Perfusion. 2008;23:237-242
11. Reddy VS, Harskamp RE, van Ginkel MW, Calhoon J, Baisden CE, Kim IS, et al. Interleukin-18 stimulates fi bronectin expression in primary human cardiac fi broblasts via PI3K-Akt-dependent NF-kappaB activation. J Cell Physiol. 2008;215:697-707.
12. Dinarello CA. Novel targets for interleukin 18 binding protein. Ann Rheum Dis. 2001;60(Suppl 3):iii18-iii24.
13. Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE. Myocardial fi brosis: Role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol. 1991;86(Suppl 3):25-31.
14. Farhadian F, Contard F, Corbier A, Barrieux A, Rappaport L, Samuel JL. Fibronectin expression during physiological and pathological cardiac growth. J Mol Cell Cardiol. 1995;27: 981-990
15. Chen H, Huang XN, Stewart AF, Sepulveda JL. Gene expression changes associated with fi bronectin-induced cardiac myocyte hypertrophy. Physiol Genomics. 2004;11; 18:273-283
16. Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F, et al. Increased expression of fi bronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol. 1997;29:2533-2543
17. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res. 2000;86:846-853
18. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149-150
19. Scanders J, Brull D, Cooper J, Thompson SR, Novick D, Stock CJ, et al. Free interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol. 2007;27:2743-2749